Dacomitinib (dacomitinib) usage guide: detailed indications, usage and precautions

1. Drug overview and indications

Dacomitinib (Dacomitinib), as an advanced tyrosine kinase inhibitor, is specifically designed to treat metastatic non-small cell lung cancer (NSCLC pan>) patient design, especially for patients with exon 19 deletion or exon 21 (L858R) substitution mutation, as the preferred first-line treatment option.

2. Mechanism of action and pharmacological properties

Dacomitinib inhibits the tyrosine kinase activity of EGFR through its unique irreversible binding method, thereby blocking the activation of the EGFR signaling pathway and effectively curbing the growth and proliferation of tumor cells. Its pharmacokinetic properties include rapid absorption, with the time to reach maximum plasma concentration being approximately 6 hours. It is widely distributed in the body, mainly metabolized by the liver, and excreted in the feces, with a small amount excreted in the urine. In terms of pharmacodynamics, Dacomitinib (Dacomitinib) significantly prolonged the progression-free survival (PFS) of EGFR mutantNSCLC patients in clinical trials.

3. Medication guidance and dosage adjustment

Recommended dose:The recommended daily dose of dacomitinib (dacomitinib) is 45 mg taken orally once and continued until disease progression or intolerable toxicity occurs.

How to take: To ensure optimal absorption, Dacomitinib (Dacomitinib) should be taken on an empty stomach, that is, at least 1 hour before or 2 hours after eating.

4. Potential side effects and countermeasures

Common side effects of dacomitinib include skin reactions (such as rash, itching), gastrointestinal discomfort (such as diarrhea, nausea, vomiting), stomatitis (such as oral ulcers, oral mucositis), nail abnormalities (such as brittleness, discoloration), fluctuations in liver function indicators (such as elevated transaminases), and rare interstitial lung diseases. In response to these side effects, patients should regularly check their skin condition, maintain oral hygiene, monitor electrolyte balance and liver function, and seek medical attention immediately if severe side effects occur.

5. Important warnings and precautions

When using dacomitinib , special attention needs to be paid to the potential risks of skin reactions, gastrointestinal problems, stomatitis, changes in liver function, and interstitial lung disease. Any serious or persistent side effects should be communicated to your doctor promptly and may require dose adjustment or medication suspension.

6. Contraindications and drug interactions

Dacomitinib is contraindicated in patients with hypersensitivity to its components and in pregnant and lactating women. At the same time, caution is required when coadministering CYP3A4 inhibitors (such as ketoconazole) or inducers (such as rifampicin) to avoid affecting drug concentrations. Close monitoring is also required when coadministered with other drugs that may affect the metabolism of dacomitinib.

7. Medication guidance for special groups

For patients with hepatic insufficiency, renal insufficiency, elderly patients, children and adolescents, the dosage of dacomitinib (dacomitinib) needs to be adjusted according to the specific situation and under the guidance of a doctor.

8. Packaging and storage information

Dacomitinib (dacomitinib) is usually available in bottles, each containing 30 tablets. Should be stored at room temperature (20-25°C), away from sunlight and moisture, and out of the reach of children.

In summary,dacomitinib (dacomitinib) as an outstanding representative ofEGFR-TKIMutated non-small cell lung cancer patients bring new treatment hope. However, its use should be strictly followed by medical advice and side effects should be closely monitored to achieve optimal therapeutic effects and reduce potential risks.